The additive diagnostic value of synthetic diffusion-weighted imaging in the diagnosis of MRI-negative prostate cancer

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400091928

Enrollment

Unknown

Registered

2024-11-06

Start date

2024-11-30

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Gold Standard:prostate puncture biopsy or surgery and pathology

Index test:Cancer detection rate of DWI sequences

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (a) Complete clinical data and comprehensive MRI reports; (b) Thorough biopsy records and results with or without RP records and results.

Exclusion criteria

Exclusion criteria: (a) Previous history of PCa treatment (such as hormone therapy, radiation therapy, cryotherapy, or surgery). (b) The interval between MRI and biopsy procedures exceeds two weeks. (c) Unable to obtain a clear diagnosis of PCa.

Design outcomes

Primary

Measure	Time frame
Cancer detection rate;	—

Countries

China

Contacts

Public ContactHU LEI

Guangdong Provincial People's Hospital(Guangdong Academy of Medical Sciences)

hulei@gdph.org.cn+86 13006141420

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026